BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1899 related articles for article (PubMed ID: 25912052)

  • 21. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.
    Schiller GJ; Tuttle P; Desai P
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):982-990. PubMed ID: 26785334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
    Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ
    Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
    Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
    Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
    Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study.
    Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
    Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
    Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
    Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
    Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV
    Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.
    Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Wakita S; Kanamori H; Usuki K; Uoshima N; Yanada M; Shono K; Ueki T; Mizuno I; Yano S; Takeuchi J; Kanda J; Okamura H; Inamoto Y; Inokuchi K; Fukuda T
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1125-1132. PubMed ID: 27040395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.
    Xuan L; Wang Y; Huang F; Fan Z; Xu Y; Sun J; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Wang Z; Jiang L; Yu C; Zhou X; Lin R; Chen Y; Tu S; Huang X; Liu Q
    Lancet Oncol; 2020 Sep; 21(9):1201-1212. PubMed ID: 32791048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD).
    Brunet S; Martino R; Sierra J
    Curr Opin Oncol; 2013 Mar; 25(2):195-204. PubMed ID: 23385863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
    Kida M; Kuroda Y; Kido M; Chishaki R; Kuraoka K; Ito T
    Int J Hematol; 2020 Aug; 112(2):243-248. PubMed ID: 32170661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
    Xuan L; Wang Y; Chen J; Jiang E; Gao L; Wu B; Deng L; Liang X; Huang F; Fan Z; Tang X; Sun J; Zhang X; Han M; Wu D; Huang X; Liu Q
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1674-1681. PubMed ID: 31009704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
    Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
    Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
    Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
    Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
    Tarlock K; Chang B; Cooper T; Gross T; Gupta S; Neudorf S; Adlard K; Ho PA; McGoldrick S; Watt T; Templeman T; Sisler I; Garee A; Thomson B; Woolfrey A; Estey E; Meshinchi S; Pollard JA
    Pediatr Blood Cancer; 2015 Jun; 62(6):1048-54. PubMed ID: 25662999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation.
    Liu YC; Hsiao HH; Lin PM; Yang WC; Chang CS; Liu TC; Hsu JF; Yang MY; Lin SF
    Genet Mol Res; 2013 Nov; 12(4):5414-23. PubMed ID: 24301914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 95.